Bethesda, Maryland-based BrainScope, which has developed mobile, non-invasive devices that help medical professionals assess Traumatic Brain Injury (TBI), raised $2.5 million, according to an SEC filing.

This brings the company's total funding to at least $6.2 million to date.

BrainScope currently offers two traumatic brain injury assessment devices. The first, Ahead 100, was cleared in November 2014. The other, Ahead 200, which the company says is a smaller, more rugged version of its Ahead 100 offering, was cleared in May. Ahead 200 consists of a headpiece with a number of EEG leads which connects to an Android smartphone that runs the diagnostic software. The device is FDA-cleared for prescription use by trained medical professionals only.

The Ahead 200 device doesn’t replace a CT Scan, but it does provide a middle ground between a CT and the questionnaire that’s much more portable and practical.

BrainScope is also developing another assessment device, which the company said has been given significant support from the DoD, GE, and the NFL.

At the end of July, BrainScope was awarded $500,000 from GE and the National Football League (NFL). At the time, the company reported it had been awarded more than $27 million of US Department of Defense research contracts for the development of its devices.

About a week later, in a post on its “Armed with Science” blog, the DoD said it is working with BrainScope to put its FDA-cleared Ahead 200 device into action. Because it's portable, BrainScope explained it would be useful to determine whether a unit needs to expend the resources to pull a military service member from the front lines and send them to a hospital.